Gilead Sciences (GILD) Depreciation & Amortization (CF) (2009 - 2026)

Gilead Sciences has reported Depreciation & Amortization (CF) for 18 years, with the latest figure at $93.0 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 4.12% year-over-year to $93.0 million; the trailing twelve-month figure through Mar 2026 stood at $366.0 million (down 4.69% YoY), and the FY2025 full-year result was $370.0 million, down 2.89% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $93.0 million, up from $90.0 million in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $98.0 million in Q2 2024, with the low at $80.0 million in Q1 2022.
• Historically, Depreciation & Amortization (CF) has averaged $89.5 million across 5 years, with a median of $91.0 million in 2023.
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) declined 7.78% — and 2024, when it rose 18.07%.
• Gilead Sciences' Depreciation & Amortization (CF) stood at $83.0 million in 2022, then advanced by 9.64% to $91.0 million in 2023, then gained by 4.4% to $95.0 million in 2024, then decreased by 5.26% to $90.0 million in 2025, then advanced by 3.33% to $93.0 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $93.0 million (Q1 2026), $90.0 million (Q4 2025), and $90.0 million (Q3 2025), per Business Quant data.